Clinical trial
Ph II CHOP+Velcade in Mediastinal LBCL
NCT00361621 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00361621 |
|---|---|
| Title | Ph II CHOP+Velcade in Mediastinal LBCL |
| Official title | Phase II Study of CHOP/Rituxan Plus VELCADE in Mediastinal Large B-cell Lymphoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Millennium Pharmaceuticals, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug, Radiation |
| Interventions | bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Radiation therapy |
| Enrollment | 3 |
| Start date | Jul 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Aug 8, 2006 |
| Last update posted | Dec 3, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: